Lexaria Announces New R&D Plans for 2026
Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the beginning of its 2026 research and development program (the "2026 R&D Program") designed to broaden pharmaceutical, intellectual property ("IP"), and business development opportunities through new and improved formulations.Information on 3 new studies from the 2026 R&D Program which are representative of the Company's...
Read more








